SVRA

+ Watchlist + Portfolio

Savara, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.05
52-Week Range: $3.34 – $7.01
Market Cap: $985.70M
P/E (TTM): —
EPS (TTM): -0.58
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 8.51
PEG Ratio: —
Return on Equity: -105.48%
Return on Assets: -50.14%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 10.13
Debt/Equity: 0.21
Total Debt: $30.41M
Free Cash Flow: $-57.19M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.08B

SVRA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$27.88M	$44.26M	$78.03M	$81.40M
Selling, General & Admin	$10.93M	$15.67M	$25.04M	$42.06M
Operating Expenses	$38.04M	$59.21M	$102.40M	$122.76M
Operating Income	-$38.04M	-$59.21M	-$102.40M	-$122.76M
EBITDA	-$37.88M	-$59.13M	-$102.27M	-$122.68M
Pretax Income	-$38.15M	-$54.70M	-$95.88M	-$118.84M
Net Income	-$38.15M	-$54.70M	-$95.88M	-$118.84M
Diluted EPS	-0.25	-0.33	-0.48	-0.53
Diluted Shares	152.77M	165.20M	198.19M	222.39M

SVRA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$52.10M	$26.59M	$15.13M	$33.18M
Receivables	$954.00K	$1.00M	$1.04M	$1.25M
Current Assets	$128.95M	$165.95M	$202.13M	$241.62M
Total Assets	$139.78M	$177.56M	$212.88M	$253.44M
Current Liabilities	$5.87M	$10.60M	$14.72M	$20.40M
Long-Term Debt	$26.08M	$26.35M	$26.62M	$29.91M
Total Debt	$26.14M	$26.49M	$26.73M	$29.91M
Total Liabilities	$32.00M	$37.19M	$41.43M	$50.30M
Retained Earnings	-$338.67M	-$393.37M	-$489.25M	-$608.09M
Shareholders' Equity	$107.78M	$140.37M	$171.45M	$203.13M
Working Capital	$123.09M	$155.35M	$187.41M	$221.22M
Net Debt	—	—	$11.49M	—

SVRA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$34.55M	-$51.06M	-$89.09M	-$101.04M
Capital Expenditure	-$9.00K	-$296.00K	-$25.00K	-$22.00K
Free Cash Flow	-$34.56M	-$51.36M	-$89.11M	-$101.06M
Depreciation & Amortisation	$167.00K	$77.00K	$130.00K	$87.00K
Stock-Based Compensation	$2.04M	$4.18M	$9.86M	$14.42M
Investing Cash Flow	$52.65M	-$57.12M	-$39.94M	-$18.44M
Financing Cash Flow	$87.00K	$82.78M	$117.58M	$137.81M
Share Repurchases	-$3.00K	-$1.21M	-$995.00K	-$5.14M
Net Change in Cash	$18.18M	-$25.40M	-$11.45M	$18.33M

SVRA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$19.16M	$20.75M	$20.59M	$20.90M	$23.40M	$21.95M
Selling, General & Admin	$9.25M	$10.65M	$9.63M	$12.53M	$15.57M	$18.99M
Operating Expenses	$27.65M	$31.44M	$30.25M	$33.42M	$38.14M	$40.97M
Operating Income	-$27.65M	-$31.44M	-$30.25M	-$33.42M	-$38.14M	-$40.97M
EBITDA	-$27.58M	-$31.37M	-$30.18M	-$33.43M	-$38.07M	-$40.87M
Pretax Income	-$26.64M	-$30.40M	-$29.56M	-$32.24M	-$37.28M	-$40.23M
Income Tax	$0.00	—	—	—	—	—
Net Income	-$26.64M	-$30.40M	-$29.56M	-$32.24M	-$37.28M	-$40.23M
Diluted EPS	-0.12	-0.14	-0.14	—	-0.15	-0.16
Diluted Shares	216.15M	216.43M	216.46M	—	253.28M	253.57M

SVRA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$19.56M	$17.44M	$16.28M	$33.18M	$38.79M	$41.80M
Receivables	$1.05M	$1.10M	$1.10M	$1.25M	$1.05M	$1.08M
Current Assets	$177.44M	$150.99M	$128.20M	$241.62M	$209.26M	$178.32M
Total Assets	$189.32M	$163.76M	$140.92M	$253.44M	$221.65M	$192.14M
Current Liabilities	$11.90M	$13.63M	$16.76M	$20.40M	$15.54M	$17.60M
Long-Term Debt	$29.52M	$29.65M	$29.78M	$29.91M	$30.07M	$30.11M
Total Debt	$29.64M	$29.74M	$29.83M	$29.91M	$30.11M	$30.41M
Total Liabilities	$41.47M	$43.28M	$46.54M	$50.30M	$45.61M	$48.48M
Retained Earnings	-$515.89M	-$546.29M	-$575.85M	-$608.09M	-$645.37M	-$685.60M
Shareholders' Equity	$147.85M	$120.48M	$94.39M	$203.13M	$176.04M	$143.66M
Working Capital	$165.55M	$137.36M	$111.44M	$221.22M	$193.73M	$160.72M
Net Debt	$9.97M	$12.22M	$13.50M	—	—	—

SVRA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$27.19M	-$26.26M	-$22.53M	-$25.06M	-$33.05M	-$29.75M
Capital Expenditure	-$3.00K	-$15.00K	-$2.00K	-$2.00K	-$54.00K	-$222.00K
Free Cash Flow	-$27.19M	-$26.28M	-$22.53M	-$25.06M	-$33.10M	-$29.97M
Depreciation & Amortisation	$68.00K	$73.00K	$75.00K	-$129.00K	$66.00K	$99.00K
Stock-Based Compensation	$2.97M	$2.67M	$3.42M	$5.36M	$10.73M	$7.76M
Investing Cash Flow	$29.33M	$24.33M	$21.47M	-$93.56M	$38.78M	$32.60M
Financing Cash Flow	$2.32M	-$49.00K	-$23.00K	$135.56M	-$195.00K	$189.00K
Share Repurchases	-$215.00K	-$114.00K	-$24.00K	-$4.79M	-$240.00K	-$5.00K
Net Change in Cash	$4.46M	-$1.98M	-$1.08M	$16.94M	$5.54M	$3.04M

Market Snapshot

About

Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disorder. Savara is advancing novel therapies through clinical trials to address significant unmet medical needs.